76 related articles for article (PubMed ID: 19434842)
1. Computational structure activity relationship studies on the CD1d/glycolipid/TCR complex using AMBER and AUTODOCK.
Nadas J; Li C; Wang PG
J Chem Inf Model; 2009 Feb; 49(2):410-23. PubMed ID: 19434842
[TBL] [Abstract][Full Text] [Related]
2. The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode.
Li Y; Girardi E; Wang J; Yu ED; Painter GF; Kronenberg M; Zajonc DM
J Exp Med; 2010 Oct; 207(11):2383-93. PubMed ID: 20921281
[TBL] [Abstract][Full Text] [Related]
3. Introduction of aromatic group on 4'-OH of α-GalCer manipulated NKT cell cytokine production.
Zhang W; Xia C; Nadas J; Chen W; Gu L; Wang PG
Bioorg Med Chem; 2011 Apr; 19(8):2767-76. PubMed ID: 21439833
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
[TBL] [Abstract][Full Text] [Related]
5. Human and mouse type I natural killer T cell antigen receptors exhibit different fine specificities for CD1d-antigen complex.
Wun KS; Ross F; Patel O; Besra GS; Porcelli SA; Richardson SK; Keshipeddy S; Howell AR; Godfrey DI; Rossjohn J
J Biol Chem; 2012 Nov; 287(46):39139-48. PubMed ID: 22995911
[TBL] [Abstract][Full Text] [Related]
6. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
[TBL] [Abstract][Full Text] [Related]
7. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
8. A molecular switch in mouse CD1d modulates natural killer T cell activation by α-galactosylsphingamides.
Wang J; Guillaume J; Janssens J; Remesh SG; Ying G; Bitra A; Van Calenbergh S; Zajonc DM
J Biol Chem; 2019 Sep; 294(39):14345-14356. PubMed ID: 31391251
[TBL] [Abstract][Full Text] [Related]
9. The molecular basis for recognition of CD1d/α-galactosylceramide by a human non-Vα24 T cell receptor.
López-Sagaseta J; Kung JE; Savage PB; Gumperz J; Adams EJ
PLoS Biol; 2012; 10(10):e1001412. PubMed ID: 23109910
[TBL] [Abstract][Full Text] [Related]
10. The crystal structure of human CD1d with and without alpha-galactosylceramide.
Koch M; Stronge VS; Shepherd D; Gadola SD; Mathew B; Ritter G; Fersht AR; Besra GS; Schmidt RR; Jones EY; Cerundolo V
Nat Immunol; 2005 Aug; 6(8):819-26. PubMed ID: 16007090
[TBL] [Abstract][Full Text] [Related]
11. 3,4-Dideoxy-3,3,4,4-tetrafluoro- and 4-OH epimeric 3-deoxy-3,3-difluoro-α-GalCer analogues: Synthesis and biological evaluation on human iNKT cells stimulation.
Golten S; Patinec A; Akoumany K; Rocher J; Graton J; Jacquemin D; Le Questel JY; Tessier A; Lebreton J; Blot V; Pipelier M; Douillard JY; Le Pendu J; Linclau B; Dubreuil D
Eur J Med Chem; 2019 Sep; 178():195-213. PubMed ID: 31185411
[TBL] [Abstract][Full Text] [Related]
12. CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.
Florence WC; Bhat RK; Joyce S
Expert Rev Mol Med; 2008 Jul; 10():e20. PubMed ID: 18601810
[TBL] [Abstract][Full Text] [Related]
13. Unique interplay between sugar and lipid in determining the antigenic potency of bacterial antigens for NKT cells.
Girardi E; Yu ED; Li Y; Tarumoto N; Pei B; Wang J; Illarionov P; Kinjo Y; Kronenberg M; Zajonc DM
PLoS Biol; 2011 Nov; 9(11):e1001189. PubMed ID: 22069376
[TBL] [Abstract][Full Text] [Related]
14. The in vivo response of invariant natural killer T cells to glycolipid antigens.
Parekh VV; Lalani S; Van Kaer L
Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
[TBL] [Abstract][Full Text] [Related]
15. CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity.
Nieuwenhuis EE; Gillessen S; Scheper RJ; Exley MA; Taniguchi M; Balk SP; Strominger JL; Dranoff G; Blumberg RS; Wilson SB
Exp Dermatol; 2005 Apr; 14(4):250-8. PubMed ID: 15810882
[TBL] [Abstract][Full Text] [Related]
16. Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells.
Chen S; Ndhlovu LC; Takahashi T; Takeda K; Ikarashi Y; Kikuchi T; Murata K; Pandolfi PP; Riccardi C; Ono M; Sugamura K; Ishii N
Eur J Immunol; 2008 Aug; 38(8):2229-40. PubMed ID: 18624295
[TBL] [Abstract][Full Text] [Related]
17. [Recognition of CD1d/glycolipid antigen complex by NKT cells and mechanisms in immune regulation].
Watarai H; Tashiro T; Chiba T; Taniguchi M
Tanpakushitsu Kakusan Koso; 2008 Sep; 53(12 Suppl):1584-9. PubMed ID: 21089371
[No Abstract] [Full Text] [Related]
18. Synthesis and evaluation of human T cell stimulating activity of an alpha-sulfatide analogue.
Franchini L; Matto P; Ronchetti F; Panza L; Barbieri L; Costantino V; Mangoni A; Cavallari M; Mori L; De Libero G
Bioorg Med Chem; 2007 Aug; 15(16):5529-36. PubMed ID: 17544671
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
Miyake S; Yamamura T
Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship studies of Bz amide-containing α-GalCer derivatives as natural killer T cell modulators.
Kishi J; Inuki S; Hirata N; Kashiwabara E; Yoshidome D; Ichihara O; Fujimoto Y
Bioorg Med Chem Lett; 2019 Apr; 29(8):970-973. PubMed ID: 30824201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
